Related Experiment Video
Updated: Dec 13, 2025

09:30
Pre-Implantation Genetic Testing for Aneuploidy on a Semiconductor Based Next-Generation Sequencing Platform
Published on: August 17, 2022
3.4K
High-resolution DNA size enrichment using a magnetic nano-platform and application in non-invasive prenatal testing
Bo Zhang1, Shuting Zhao, Hao Wan
1Apostle Inc., San Jose, CA 95134, USA. bzhang@apostlebio.com dge@apostlebio.com.
The Analyst
|August 5, 2020
Summary
MiniEnrich is a new workflow that precisely sizes DNA fragments under 200 bp. This high-resolution DNA enrichment improves non-invasive prenatal testing (NIPT) accuracy and enables earlier testing by increasing fetal DNA fraction.
Area of Science:
- Biotechnology
- Genomics
- Molecular Biology
Background:
- Current DNA sizing methods lack resolution for fragments under 200 bp.
- This limitation hinders non-invasive prenatal testing (NIPT) by failing to differentiate fetal and maternal DNA (143 bp vs. 166 bp peaks).
- Existing NIPT workflows face sample rejection and reduced clinical utility due to this sizing gap.
Purpose of the Study:
- To develop a high-resolution DNA size enrichment workflow for fragments under 200 bp.
- To exploit the size difference between fetal and maternal cell-free DNA for improved NIPT.
- To enhance the fetal fraction in maternal plasma for more accurate NIPT.
Main Methods:
- Developed MiniEnrich, an automatable magnetic nano-platform workflow.
- Utilized two types of magnetic nanoparticles for high-resolution DNA filtering and recovery.
- Applied the method to enrich fetal DNA fragments from maternal plasma.
Main Results:
- Achieved high-resolution DNA size enrichment for fragments under 200 bp.
- Increased the average fetal fraction from 13% to 20% post-enrichment, as measured by plasma DNA sequencing.
- Demonstrated the workflow's ability to exploit the 20 bp size difference between fetal and maternal DNA.
Conclusions:
- MiniEnrich offers a novel tool for precise DNA size enrichment below 200 bp.
- This technology has the potential to improve NIPT accuracy, rescue rejected samples, and enable earlier NIPT.
- The workflow may also advance screening for fetal monogenic disorders, liquid biopsy analysis, and autoimmune disease diagnosis.

